StockData
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. (ELDN) company profile

ELDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.98+0.01 (+0.51%)

Close on Nov 17, 2026Market cap $160.90MP/E –Yield –

About Eledon Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company that develops immunomodulatory therapies targeting the CD40 Ligand pathway. Its primary investigational product candidate is tegoprubart, an antibody designed to block CD40L signaling to suppress immune responses and promote immune tolerance without causing lymphocyte depletion or platelet activation. The company focuses on developing treatments to prevent organ rejection in both human-to-human allograft and animal-to-human xenograft transplantation, especially kidney transplants, as well as therapies for amyotrophic lateral sclerosis. As a clinical-stage development company without approved commercial products, its end users are intended to be transplant recipients and individuals with neurodegenerative conditions.

The company operates within the United States and conducts business across a single operating segment dedicated to pharmaceutical research and clinical development. It relies on external contract research organizations and third-party manufacturers to carry out testing and produce candidate materials. The company maintains its principal executive offices in Irvine, California.

Summary of the business section of Eledon Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Eledon Pharmaceuticals, Inc.
Headquarters
Irvine, CA
Address
19800 Macarthur Blvd., Suite 250 92612
Phone
(949) 238-8090
Website
eledon.com
Employees
33, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Crowe LLP, Los Angeles, California

Stock & identifiers

Ticker
ELDN
Former tickers
NVUS until Jan 5, 2021; TKAI until Aug 9, 2017
Exchange
Nasdaq
IPO date
Sep 18, 2014
Shares outstanding
81M, Aug 10, 2026
Public float
$145.17M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-18 reverse, Oct 5, 2020; 1-for-291 reverse, Aug 9, 2017; 1-for-9 reverse, May 11, 2017
SEC CIK
1404281
CUSIP
28617K101
ISIN
US28617K1016
FIGI
BBG00241S542
Share class FIGI
BBG00241S579
LEI
549300S17CAM13O43606
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David-Alexandre C. GrosChief Executive Officer, Director363,454
Steven PerrinPresident, Director153,353
Paul Sean LittleChief Financial Officer10,000
Bryan E. SmithGeneral Counsel, Corporate Sec–
Jan HillsonDirector3,430
James A. Robinson Jr.Director3,430
Allan KirkDirector3,430
John S. McBrideDirector3,430
Keith KatkinDirector8,575
June LeeDirector3,430

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.22M-$315.00K$1.64M$66–
FY2024$5.64M$6.79M$3.83M$181–
FY2023$2.55M$404.58K$1.43M$79–
FY2022$1.12M-$1.98M$1.05M$52–
FY2021$747.50K-$4.79M$2.06M$29–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
David-Alexandre C. Gros
Chief Executive Officer
$613.20K$268.66K$1.96M$349.52K$21.69K$3.22M-43%
Steven Perrin
President and Chief Scientific Officer
$484.92K$109.08K$795.05K$284.28K$22.95K$1.70M-63%
Paul Little
Chief Financial Officer
$479.23K$303.00K$572.57K$215.17K$22.98K$1.59M-48%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 18, 2014
Offer price
$15.00
Securities offered
6,480,000
Gross proceeds
$97.20M
Exchange
Nasdaq
First trading day
Sep 17, 2014
First-day close
$23.76+58.4%
Lock-up ends (est.)
Mar 16, 2015

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 13, 2026, Eledon had 33 employees, all of whom are full-time.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 14, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 7, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 14, 2024Late filingNotification of late filing
Jul 12, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 22, 2020Name changeName changed from Novus Therapeutics, Inc. to Eledon Pharmaceuticals, Inc.
Sep 15, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 23, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 7, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 9, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 12, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
May 15, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 15, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
May 4, 2017Name changeName changed from Tokai Pharmaceuticals Inc to Novus Therapeutics, Inc.
Apr 7, 2017Merger voteDefinitive merger proxy statement
Mar 9, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 18, 2014IPOInitial public offering priced (424B4 prospectus)
Sep 12, 2014ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?